buchspektrum Internet-Buchhandlung

Neuerscheinungen 2016

Stand: 2020-02-01
Schnellsuche
ISBN/Stichwort/Autor
Herderstraße 10
10625 Berlin
Tel.: 030 315 714 16
Fax 030 315 714 14
info@buchspektrum.de

Kim Heidenreich

New Therapeutics for Traumatic Brain Injury


Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration
Herausgegeben von Heidenreich, Kim
2016. 352 S. 229 mm
Verlag/Jahr: ACADEMIC PRESS 2016
ISBN: 0-12-802686-3 (0128026863)
Neue ISBN: 978-0-12-802686-1 (9780128026861)

Preis und Lieferzeit: Bitte klicken


New Therapeutics for Traumatic Brain Injury: Prevention of Secondary Brain Damage and Enhancement of Repair and Regeneration explores traumatic brain injury (TBI), a major cause of death and disability throughout the world. The delayed nature of the secondary injury phase suggests that there is a therapeutic window for pharmacological interventions or other approaches to prevent progressive tissue damage and improve functional outcomes. It is now apparent that therapeutic interventions should entail both protective and repair/regeneration strategies depending on the phase of brain injury.

This book describes emerging experimental strategies for the treatment of TBI, including new anti-inflammatory or anti-apoptotic therapeutics that limit brain damage, and novel or repurposed drugs that enhance repair or regeneration of the brain after injury.

Comprehensive overview of basic approaches and translational development of new therapies for TBI
Edited by a prominent TBI researcher that includes contributions by leading global researchers in the field
Presents a great resource for researchers and practitioners to learn more about the many evolving preclinical studies and clinical trials currently underway, and the challenges of bringing translational studies in TBI to the clinic
Part I. Interventional Therapies for TBI Previously or Currently in Phase 3 Clinical Trials 1. Why Did the Phase III Clinical Trials for Progesterone in TBI Fail? An Analysis of Three Potentially Critical Factors 2. Hypothermia for Traumatic Brain Injury: Current Evidence and Future Directions 3. The Future of TBI: Hyperbaric Oxygen as a Primary Therapeutic Approach

Part II. Repurposing FDA Approved Drugs for TBI Treatment 4. Erythropoietin and Its Derivatives: Mechanisms of Neuroprotection and Challenges in Clinical Translation 5. Atorvastatin in the Treatment of Traumatic Brain Injury 6. The Application of Glibenclamide in Traumatic Brain Injury 7. Perispinal Etanercept for Traumatic Brain Injury

Part III. Interventional Drugs for TBI in Phase 1-2 Clinical Trials 8. Nitric Oxide Synthase Inhibitors in Traumatic Brain Injury 9. Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury

Part IV. Interventional Drugs for TBI in Preclinical Development 10. The Use of Estrogen for the Treatment of Traumatic Brain Injury 11. Voltage-Gated Calcium Channel Blockers for the Treatment of Traumatic Brain Injury 12. 5-Lipoxygenase-Activating Protein Inhibitors: Promising Drugs for Treating Acute and Chronic Neuroinflammation Following Brain Injury 13. Carbonyl Scavenging as an Antioxidant Neuroprotective Strategy for Acute Traumatic Brain Injury 14. TrkB Receptor Agonist 7,8-Dihydroxyflavone and Its Therapeutic Potential for Traumatic Brain Injury 15. Ceftriaxone Treatment of TBI

Part V. Drugs for TBI Rehabilitation 16. Memantine: A Safe and Tolerable NMDA Antagonist with Potential Benefits in Traumatic Brain Injury 17. Interventional Drugs for TBI Rehabilitation of Cognitive Impairment: The Cholinesterase Inhibitor Rivastigmine 18. Docosahexaenoic Acid and Omega 3 Fatty Acids 19. Treatment of Mood Disorders Following Traumatic Brain Injury